.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,664,278

« Back to Dashboard

Details for Patent: 8,664,278

Title:Stabilized compositions of volatile alkylating agents and methods of using thereof
Abstract: A composition for treating psoriasis, mycosis fungoides or alopecia comprising bis-(2-chloroethyl)methylamine or an HX salt and the pharmaceutically acceptable excipient HOCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OR.sub.79, wherein R.sub.79 is a linear alkyl group having 1-6 carbon atoms.
Inventor(s): Alonso; Robert (Wayne, PA), Crooks; Peter A. (Little Rock, AR), Pimley; Mark A. (West Chester, PA)
Assignee: Actelion Pharmaceuticals, Ltd. (Allschwil, CH)
Filing Date:Jan 07, 2013
Application Number:13/735,710
Claims:1. A method of manufacturing a pharmaceutical composition, the method comprising combining bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient; wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is resent in an amount of about 0.001 percent to about 2.0 percent by weight of the composition; and the pharmaceutically acceptable excipient is a compound of the formula HOCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OR.sub.79, wherein R.sub.79 is a linear alkyl group having 1-6 carbon atoms.

2. The method of manufacturing according to claim 1, wherein the pharmaceutical composition is in a non-aqueous carrier.

3. The method of manufacturing according to claim 1 or 2, wherein the pharmaceutical composition does not include petrolatum or ethanol.

4. The method of claim 1, wherein the bis-(2-chloroethyl)methylamine is in the form of an acid-addition or base-addition salt.

5. The method of claim 4, comprising the acid-addition salt, wherein the acid-addition salt is an HCl, HBr, HI, H.sub.2SO.sub.4, or HNO.sub.3 salt.

6. The method of claim 5, wherein the acid-addition salt is an HCl salt.

7. The method of claim 1, wherein the pharmaceutically acceptable excipient is a compound of the formula HOCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OR.sub.79, wherein R.sub.79 is a linear alkyl group having 2 carbon atoms (ethoxy diglycol reagent).

8. The method of claim 1, wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.01 percent to about 0.04 percent by weight of the composition.

9. The method of claim 1, wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.015 percent to about 0.030 percent by weight of the composition.

10. The method of claim 6, wherein the pharmaceutically acceptable excipient is a compound of the formula HOCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OR.sub.79, wherein R.sub.79 is a linear alkyl group having 2 carbon atoms (ethoxy diglycol reagent).

11. The method of claim 1, further comprising combining a second pharmaceutically acceptable excipient, wherein the second pharmaceutically acceptable excipient is selected from the group consisting of butylated hydroxytoluene, edetate disodium, benzyl alcohol, hydroxypropylcellulose, isopropyl alcohol, menthol, propylene glycol, polypropylene glycol, polyethylene glycol, ethylene glycol, glycerin, and combinations thereof.

12. The method of claim 11, wherein the second pharmaceutically acceptable excipient is butylated hydroxytoluene.

13. The method of claim 11, wherein the second pharmaceutically acceptable excipient is edetate disodium.

14. The method of claim 11, wherein the second pharmaceutically acceptable excipient is isopropyl alcohol.

15. The method of claim 11, wherein the second pharmaceutically acceptable excipient is menthol.

16. The method of claim 11, wherein the second pharmaceutically acceptable excipient is propylene glycol.

17. The method of claim 11, wherein the second pharmaceutically acceptable excipient is glycerin.

18. The method of claim 11, wherein the second pharmaceutically acceptable excipient is hydroxypropylcellulose.

19. The method of claim 11, wherein the second pharmaceutically acceptable excipient comprises butylated hydroxytoluene, edetate disodium, hydroxypropylcellulose, isopropyl alcohol, menthol, propylene glycol, and glycerin.

20. The method of claim 10, further comprising combining a second pharmaceutically acceptable excipient, wherein the second pharmaceutically acceptable excipient is selected from the group consisting of butylated hydroxytoluene, edetate disodium, benzyl alcohol, hydroxypropylcellulose, isopropyl alcohol, menthol, propylene glycol, polypropylene glycol, polyethylene glycol, ethylene glycol, glycerin, and combinations thereof.

21. The method of claim 20, wherein the second pharmaceutically acceptable excipient comprises butylated hydroxytoluene, edetate disodium, hydroxypropylcellulose, isopropyl alcohol, menthol, propylene glycol, and glycerin.

22. The method of claim 1, 11, or 21, further comprising combining an organic acid in an amount of about 1 percent to about 15 percent by weight of the composition, wherein the organic acid is selected from the group consisting of oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, 2-acetoxybenzoic acid, acetic acid, phenylacetic acid, propionic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, ascorbic acid, maleic acid, hydroxymaleic acid, glutamic acid, salicylic acid, sulfanilic acid, fumaric acid, and combinations thereof.

23. The method of claim 22, wherein the organic acid is lactic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc